“Defendant sells a line of fake collagen cosmetic products that do not contain any collagen whatsoever,” say plaintiffs Mocha Gunaratna and Renee Camenforte in their complaint against Dr. Dennis Gross Skincare, LLC (DDG) lodged in California’s Central District.
Dr. Dennis Gross Skincare Could Be Headed To Trial Over Alleged ‘Fake Collagen Cosmetic Products’
After California’s Central District denied Dr. Dennis Gross Skincare’s motion to dismiss in November 2020 and granted class certification to plaintiffs in April 2023, the New York-based defendant seems intent on continuing the fight. DDG has argued that “collagen amino acids” and “vegan” disclosures on its C + Collagen product labels sufficiently convey to consumers that animal byproducts are not present in the formulas.
More from Legal
• By
Despite questions surrounding the SEC rule, including disputes being litigated in the US Eighth Circuit, companies must prepare to meet the new climate disclosure requirements in addition to related mandates in California and abroad. Experts emphasize opportunities beyond compliance.
• By
California authorities say predominance of retailers licensed to sell hemp are compliant with ban published effective on 3 October through emergency regulation. But hemp industry’s contesting the regulation in state court, arguing state authorities inappropriately used emergency action to change state law on hemp products legislature passed in 2021.
• By
Plaintiffs in California federal courts seek restitution, damages, and other relief on behalf of themselves and consumers nationwide, whom allegedly were deceived by “Plant-Based” representations on Aveeno and Neutrogena Makeup Removing Wipes.
• By
Filed on 20 August by Pensacola, FL-based law firm Aylstock, Witkin, Kreis & Overholtz (AWKO) on behalf of an unnamed client, the petition points to benzene study data unconnected to Valisure on unheated benzoyl peroxide products, but is light on details of how it was conducted.
More from Policy & Regulation
• By
Data from the US Food and Drug Administration indicated that two hair dye ingredients are formulated in eye makeup and dermal application products, prompting a Cosmetic Ingredient Review panel to conclude one dye is unsafe for such uses and discouraging those uses in the other dye.
• By
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
• By
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.